thiazolyl blue has been researched along with Cardiac Hypertrophy in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Garcia, JG; Gupta, MP; Kim, G; Moreno-Vinasco, L; Pillai, VB; Samant, S; Sundaresan, NR | 1 |
| Granberry, MC; Kennedy, RH; Liu, H; Melchert, RB | 1 |
2 other study(ies) available for thiazolyl blue and Cardiac Hypertrophy
| Article | Year |
|---|---|
Nampt secreted from cardiomyocytes promotes development of cardiac hypertrophy and adverse ventricular remodeling.
Topics: Animals; Animals, Newborn; Cardiomegaly; Coloring Agents; Echocardiography; Enzyme-Linked Immunosorbent Assay; Fibroblasts; Fibrosis; Immunohistochemistry; Leucine; Mice; Mice, Knockout; Mice, Transgenic; Mitogen-Activated Protein Kinases; Myocytes, Cardiac; NFATC Transcription Factors; Nicotinamide Phosphoribosyltransferase; Rats; Real-Time Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Tetrazolium Salts; Thiazoles; Ventricular Remodeling | 2013 |
Lovastatin inhibits phenylephrine-induced ERK activation and growth of cardiac.
Topics: Animals; Animals, Newborn; Anticholesteremic Agents; Blotting, Western; Cardiomegaly; Cells, Cultured; Coloring Agents; Enzyme Activation; Heart; Lovastatin; Mitogen-Activated Protein Kinases; Myocardium; Phenylephrine; Phosphorylation; Pravastatin; Propidium; Rats; Rats, Sprague-Dawley; Tetrazolium Salts; Thiazoles | 2001 |